# Safety and Immunogenicity of a Chlamydia Vaccine CTH522

> **NCT03926728** · PHASE1 · COMPLETED · sponsor: **Statens Serum Institut** · enrollment: 65 (actual)

## Conditions studied

- Trachoma

## Interventions

- **BIOLOGICAL:** CTH522-CAF01 IM
- **BIOLOGICAL:** CTH522-CAF09b IM
- **BIOLOGICAL:** CTH522 ID
- **BIOLOGICAL:** CTH522 TO
- **BIOLOGICAL:** Placebo (Saline)

## Key facts

- **NCT ID:** NCT03926728
- **Lead sponsor:** Statens Serum Institut
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-17
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2024-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03926728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03926728, "Safety and Immunogenicity of a Chlamydia Vaccine CTH522". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03926728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*